Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates


Posted on 24 July 2018 | Posted in Evolocumab
Trial EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) Identifier: NCT03287609

Aim To evaluate the safety and effectiveness of evolocumab versus placebo, administered in the acute phase of ACS, for reduction of low-density lipoprotein cholesterol (LDL-C levels) within 8 weeks in patients receiving guideline-recommended high-intensity statin treatment (atorvastatin 40mg daily).
Study design Randomized, double-blind, parallel-group placebo-controlled trial with quadruple masking (subject, care provider, investigator, outcomes assessor). Patients were randomized to evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
Patient population 308 patients with acute coronary syndrome (ACS)
Primary efficacy endpoint Percent change in calculated LDL‑C in the intent to treat (ITT) population from baseline to week 8]
Other endpoints Secondary:

Number of patients with adverse events and serious adverse events
For other outcomes – see link

Key results Ongoing study; estimated primary completion March 31, 2019
Author conclusion -
Publication -





Related content